Patent Grant
8067602
This application claims priority to Chinese Patent Application No. 200810002503.7, filed Jan. 4, 2008, for “ASYMMETRIC CYANINE FLUORESCENT DYES, COMPOSITIONS COMPRISING THE SAME AND THEIR USE IN STAINING BIOLOGICAL SAMPLES,” the disclosure of which is fully incorporated herein by reference.
The present disclosure relates to fluorescent dyes. More particularly, the present disclosure relates to asymmetric cyanine fluorescent dyes useful in staining biological samples, compositions comprising the same and their use in staining biological samples.
Asymmetric cyanine fluorescent dyes are disclosed. Compositions including asymmetric cyanine fluorescent dyes and their use in staining biological samples are also disclosed.
The incorporation and rapid development of new sciences and technologies such as lasers, microprocessors and electronics have promoted the application of fluorescent analysis techniques. Particularly, with the advent of biochips having fluorescent dyes as the labeling agent, the fluorescent analysis techniques find wide application in cell immunology, microbiology, molecular biology, molecular genetics, pathology, clinical laboratory science, and botany, among others. The development of fluorescent dyes plays a pivotal role in the progress of fluorescent analysis techniques.
Early-used dyes include new methylene blue (NMB), brilliant cresyl blue (BCB), pyronin Y and ethidium bromide, etc. They form complexes with nucleic acid molecules through intercalation or electrostatic attraction and therefore enhanced fluorescence can be observed under a microscope. However, these dyes can form dye complexes by themselves that are not distinctly distinguished from the complexes formed with nucleic acids, resulting in strong background interference in fluorescence. Also, these dyes have a low fluorescence quantum efficiency, which decreases the degree of fluorescent enhancement and affects the accuracy of detection results.
Acridine orange is also used in fluorescent analysis by virtue of the fluorescence-enhancing complexes that it forms with nucleic acids. But these kinds of dye molecules may cause optical quenching among each other in the process of energy transfer, which results in the dye-nucleic acid complexes emitting no fluorescent and therefore influences the authenticity of detection results. Acridine orange may also have a strong interaction with the plastic tubings in flow cytometers, leading to increased intensity of background fluorescence. A longer time of washing of the tubings in the instruments is required for cleaning the post-detection residual dyes and ensuring the accuracy of detection results, and thus reduces the analyzing efficiency of the instruments.
U.S. Pat. No. 4,957,870 discloses a thiazole blue dye useful in the detection of nucleic acids and blood reticulocytes. The excitation wavelength of this dye is 488 nm, which requires a costly laser as the light source, and therefore increases the cost in equipment. Moreover, this kind of dye requires a longer incubation time to better bind to nucleic acids.
U.S. Pat. No. 5,994,138 discloses a dye for staining blood reticulocytes. This dye requires a reaction condition of above 35° C. to bring good detection results, which poses a higher demand on the use conditions of instruments.
Although cyanine fluorescent dyes in current use such as TOTAB, TOTIN, TO-PRO-3, PO-PRO-2 and BO-PRO-2 or the like [K. M. Sovenyhazy, J. A. Bordelon, J. T. Petty. Nucleic Acids Res, 2003, 31, 2561] have absorption and emission wavelengths that are both in the near-infrared region (670-1000 nm), their complex molecular structures, long synthesis routes and low synthesis yields and therefore high price limit their scope of use.
Therefore, it would be desirable to develop novel fluorescent dyes which may include one or more of the following attributes: (1) they do not fluoresce when unbound to nucleic acids but have a high fluorescence quantum yield when bound to nucleic acids; (2) they have a light spectrum in the near-infrared region so that interference from background fluorescence can be avoided; (3) they can be excited near 633 nm so that low-price lasers can be used as the light source; (4) they have a certain level of water solubility together with a certain ability to penetrate cell membranes.
In one embodiment there is provided a compound having the structure of the following general formula I:
wherein
n is 1, 2 or 3;
X is C(CH3)2, O, S or Se;
R1 and R2 are each independently selected from at least one of the following: H, OH, C1-18alkyl, C1-6alkyl-OR5, C1-18alkylsulfo, phenyl and halogen;
R3 and R4 are each independently selected from at least one of the following: C1-18alkyl-COOR6, C1-18alkyl-OR6, and benzyl, wherein said benzyl is optionally substituted with one or more substituents selected from at least one of the following: halogen, hydroxyl, sulfhydryl, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, amino, alkylamino, amido and carboxyl, provided that R3 and R4 are not simultaneously benzyl, and R4 is not C1-18alkyl-OR6 when R3 is benzyl;
R5 is C1-18alkyl or H;
R6 is C1-18alkyl, H or phenyl, wherein said phenyl is optionally substituted with one or more substituents selected from at least one of the following: halogen, hydroxyl, sulfhydryl, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, amino, alkylamino, amido and carboxyl; and
Y− is an anion.
In another aspect there is provided a conjugate comprising the compounds of the above formula I.
In yet another aspect there is provided a composition useful in staining biological samples, said composition comprising the compounds of the above formula I or conjugates thereof.
In still another aspect there is provided a use of the compounds of the above formula I or conjugates or compositions thereof in staining biological samples.
The compounds, conjugates or compositions disclosed may stain biological samples such as nucleic acids, leucocytes, erythroblasts, reticulocytes and the like, and the complexes thus formed have an emission wavelength in the near-infrared region, which avoids the interference from background fluorescence of the organisms per se, improves the accuracy of detection results and permits their use on a flow cytometer as the staining agent for various biological samples.
Definitions
Unless otherwise specified, the following terms as used herein have the following meanings.
The term “alkyl” as used herein individually or in combination with other groups refers to straight or branched alkyl groups containing 1-18 carbon atoms, such as 1-12, or alternatively 1-8, or 1-6 carbon atoms. Reference to a single alkyl such as “n-propyl” specifically means a straight alkyl group, while reference to a single branched alkyl such as “isopropyl” specifically means a branched alkyl group. For example, “C1-6alkyl” includes C1-4alkyl, C1-3alkyl, methyl, ethyl, n-propyl, isopropyl and tert-butyl. The like rules also apply to other groups as used throughout the present specification.
The term “alkoxy” as used herein refers to the “alkyl” as defined above in combination with the group —O—, wherein said “alkyl” contains 1-18 carbon atoms, such as 1-12, or alternatively 1-8, or 1-6 carbon atoms, such as methoxy, ethoxy, propoxy and the like.
The term “halogen” as used herein includes fluorine, chlorine, bromine and iodine.
The term “benzyl” as used herein refers to —CH2-Ph group. Modification of a benzyl group by the phrase “optionally substituted with” means that the benzyl group either can exist in an unsubstituted form, or can be substituted with a suitable substituent at any suitable position. Suitable substituents include, but are not limited to, halogen, hydroxyl, sulfhydryl, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, amino, alkylamino, amido, carboxyl, etc., so long as the compounds finally formed have the properties as contemplated by the present disclosure. In one embodiment, the benzyl group is optionally substituted with halogen, hydroxyl, sulfhydryl, cyano, nitro or amino.
The term “heterocyclyl” as used herein refers to a single ring or fused ring system comprising 3-14 ring members, such as 3-10, or alternatively 3-6 ring members and containing one or more heteroatoms selected from nitrogen, oxygen and sulfur.
The term “biological sample” as used herein includes but is not limited to nucleic acids and leucocytes, erythroblasts, and reticulocytes in the blood, etc.
Exemplary Compounds
In one embodiment a compound has the structure of the following general formula I:
wherein
n is 1, 2 or 3;
X is C(CH3)2, O, S or Se;
R1 and R2 are each independently selected from at least one of the following: H, OH, C1-18alkyl, C1-6alkyl-OR5, C1-18alkylsulfo, phenyl and halogen;
R3 and R4 are each independently selected from at least one of the following: C1-18alkyl-COOR6, C1-18alkyl-OR6, and benzyl, wherein said benzyl is optionally substituted with one or more substituents selected from at least one of the following: halogen, hydroxyl, sulfhydryl, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, amino, alkylamino, amido and carboxyl, provided that R3 and R4 are not simultaneously benzyl, and R4 is not C1-18alkyl-OR6 when R3 is benzyl;
R5 is C1-18alkyl or H;
R6 is C1-18alkyl, H or phenyl, wherein said phenyl is optionally substituted with one or more substituents selected from at least one of the following: halogen, hydroxyl, sulfhydryl, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, amino, alkylamino, amido and carboxyl; and
Y− is an anion.
In one embodiment n is 1 or 2, and in another n is 1.
In one embodiment X is C(CH3)2, O or S; or alternatively, X is C(CH3)2 or S; or X is S.
In one embodiment R1 and R2 are each independently selected from at least one of the following: H and C1-18alkyl; alternatively, R1 and R2 are each independently selected from at least one of the following: H and C1-6alkyl; and in yet another embodiment R1 and R2 are both H.
In one embodiment, R3 and R4 are each independently selected from at least one of the following: C1-8alkyl-COOR6, C1-8alkyl-OR6, and benzyl, wherein said benzyl is optionally substituted with one or more substituents selected from at least one of the following: halogen, hydroxyl, sulfhydryl, cyano, nitro and amino. Alternatively, R3 and R4 are each independently selected from at least one of the following: C1-6alkyl-COOR6, C1-6alkyl-OR6, and benzyl, wherein said benzyl is optionally substituted with one or more substituents selected from at least one of the following: halogen, hydroxyl, sulfhydryl, cyano, nitro and amino. In another embodiment, R5 is H or C1-12alkyl, or alternatively, R5 is H or C1-6alkyl.
In one embodiment, R6 is C1-6alkyl or phenyl, wherein said phenyl is optionally substituted with one or more substituents selected from at least one of the following: halogen, hydroxyl, sulfhydryl, cyano, nitro, alkyl, aryl, alkoxy, heterocyclyl, haloalkyl, amino, alkylamino, amido and carboxyl.
Y− represents an anion, which can be any suitable anion, including but not limited to inorganic anions or organic anions, such as halogen ions, ClO4−, PF6−, CF3SO3−, BF4−, acetate or p-toluenesulfonate anions.
The compounds disclosed can be directly used for staining biological samples in the form of salts as described herein. Alternatively, in one embodiment, the compounds disclosed can exist in the form of derivatives of the compounds of formula I, said derivatives including, but not limited to, conjugates.
Subsequently or simultaneously with mixing a red blood cell lysing agent, the stock solution of the fluorescent dye is added to fluorescently label the white blood cells. When the blood sample is mixed with the reagent disclosed herein, the total volume of the blood sample and the reagent may ensure that a sufficient concentration of cells will pass through the detection channel of the apparatus. The reagent composition may dilute the blood sample to a proportion of 10:1, 50:1 or 100:1, or any value in any of the above ranges, so long as the dilution meets the requirements of practical use. Such adjustment is within the capability of those skilled in the art with the aid of the present disclosure.
Typically, conjugates are used in the fluorescence activated cell sorter (FACS). “Conjugates” as used herein refer to the compounds formed by attaching the fluorescent dyes disclosed to other molecules via covalent bonds. Molecules that can be conjugated with the fluorescent dyes disclosed may be those that specifically bind to cells or cell components, including, but not limited to, antibodies, antigens, receptors, ligands, enzymes, substrates, coenzymes or the like. Generally, the test sample is incubated with the fluorescent conjugates for a period of time so that the fluorescent conjugates bind specifically to certain cells or cell components in the test sample. The binding of the fluorescent conjugates to the cells or cell components is also referred to as staining. The staining step can be repeated in sequence several times, or a variety of conjugates can be used for concurrent multistaining. After staining, analysis of the sample is conducted in the fluorescence activated cell sorter, wherein the excitation light source excites the fluorescent dyes disclosed in the conjugates and the detection apparatus detects the emitted light generated by the excited fluorescent dyes.
Alternatively, in another embodiment, the fluorescent conjugates can also be used in solid phase immunological assays, e.g., in sandwich immunological assays. The techniques for solid phase immunological assays are well known in the art and can be found in standard textbooks. The fluorescent conjugates disclosed can be used as the various suitable components in solid phase immunological assays.
Methods for Preparing Exemplary Compounds
The compounds disclosed can be prepared using general methods known in the art. See, for example, Chinese Patent Application CN200710137258.6, which is incorporated herein by reference. In particular, the asymmetric cyanine fluorescent dyes disclosed are generally synthesized by the following steps. First, react unsubstituted or substituted 2-methylbenzothiazole, 2-methylbenzoxazole or 2,3,3-trimethyl-3H-indoline as the starting material with a halide of formula R3X (X is F, Cl, Br or I) in a molar ratio of 1:1-2 by refluxing in toluene for 12-36 hours to obtain the quaternary ammonium salt intermediates of formula II:
wherein X, R1, R3 and Y− are as defined in the compounds of the above formula I.
Next, condense the resulting quaternary ammonium salt intermediates of formula II with linking molecules to obtain the compounds of formula III:
wherein X, n, R1, R3 and Y− are as defined in the compounds of formula I, and the linking molecules can be N,N′-diphenylformamidine or higher homologues thereof.
Then, obtain substituted or unsubstituted 4-methylquinolinium salt intermediates in a process similar to that used in the synthesis of the compounds of formula II. Finally, reflux the 4-methylquinolinium salt intermediates with the compounds of formula III in pyridine or acetic anhydride to obtain the desired asymmetric cyanine fluorescent dyes. The resulting fluorescent dyes can be recovered using separation and purification techniques well known in the art to achieve the desired purity.
The raw materials used in the present disclosure are commercially available, or can be readily prepared from raw materials known in the art using methods known to those skilled in the art or methods disclosed in the art.
It is appreciated that certain of the various ring substituents in the compounds disclosed may be introduced through standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process disclosed. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical arts. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminum trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminum trichloride) under Friedel Crafts conditions; and the introduction of a halogen group. Particular examples of modifications include the reduction of a nitro group to an amino group by, for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
The fluorescent conjugates comprising the compounds of formula I can be synthesized using any conventional methods known in the art.
Exemplary Compositions
The present disclosure also provides compositions comprising the above-mentioned compounds of formula I or conjugates thereof, which are used for staining biological samples The solution may be finally adjusted to about pH 7.
The compositions may comprise, besides the compounds of formula I or conjugates thereof, other components required for staining biological samples, e.g., solvents, osmotic regulating agents, pH regulating agents, surfactants, etc. The compositions may exist in the form of an aqueous solution, or in other suitable forms that can be formulated into solution using water prior to usage.
Usage of the Exemplary Compounds or Compositions
The present disclosure further provides a method for staining biological samples using the above-mentioned compounds of the formula I or conjugates thereof, or compositions comprising the above-mentioned compounds of formula I or conjugates thereof. The method may include the step of contacting the above-mentioned compounds of formula I or conjugates thereof, or the compositions comprising the above-mentioned compounds of formula I or conjugates thereof with the biological samples. The term “contacting” as used herein may include contacting in solution or in solid phase.
Characteristics
From the above description and common knowledge familiar to those skilled in the art, the various characteristics of the fluorescent dyes disclosed may include, but are not limited to the following: (1) The compounds provided may stain DNA, and the dye/DNA complexes formed have a fluorescence emission strength 40-100 times higher than that of the dyes themselves. (2) The compounds provided also stain RNA, and the dye/RNA complexes formed have a fluorescence emission strength 20-40 times higher than that of the dyes themselves. (3) The dye/nucleic acid complexes may have an emission wavelength in the range of 640 nm-900 nm in the near-infrared region, which avoids interference from the background fluorescence of the organisms per se and may improve the accuracy of detection results. (4) The compounds provided may be used on a flow cytometer as the staining agent for reticulocytes, leucocyte and erythroblast in the blood. (5) The compounds provided, when bound to nucleic acids, may be excited by 633-nm wavelength light emitted by a red semiconductor laser, thereby reducing the equipment cost.
The present disclosure is further illustrated by the following particular examples to which or by which the present disclosure is not limited, as is appreciated by one skilled in the art.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-ethyl hexanoate-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 6 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was then filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to obtain an orange-red solid product with a yield of 42%. Into 4.0 mmol of the obtained reaction product were added 4.2 mmol of 1-benzyl-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate dark purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:10 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-1 compound in a yield of 53%. MS (EI) C34H35BrN2O2S m/z: 535.2 [M-Br]+.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-(2-hydroxyethyl)-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 6 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to afford an orange-red solid product with a yield of 41%. Into 4.0 mmol of the obtained reaction product were added 4.5 mmol of 1-ethyl butanoate-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:18 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-2 compound in a yield of 49%. MS (EI) C27H29BrN2O3S: m/z: 461.2[M-Br]+.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-(2-phenoxyethyl)-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 5 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was then filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to afford an orange-red solid product with a yield of 47%. Into 4.0 mmol of the obtained reaction product were added 4.2 mmol of 1-(2-hydroxyethyl)-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:15 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-3 compound in a yield of 40%. MS (EI) C29H27BrN2O2S m/z: 467.2 [M-Br]+.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-ethyl butanoate-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 6 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to afford an orange-red solid product with a yield of 40%. Into 4.0 mmol of the obtained reaction product were added 4.2 mmol of 1-(4-methoxyphenyl)-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:8 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-4 compound in a yield of 61%. MS (EI) C33H33BrN2O3S m/z: 537.2[M-Br]+.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-ethyl butanoate-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 6 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was then filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to obtain an orange-red solid product in a yield of 40%. Into 4.0 mmol of the obtained reaction product were added 4.2 mmol of 1-(4-fluorophenyl)-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:8 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-5 compound in a yield of 49%. MS (EI) C32H30BrFN2O2S m/z: 525.2 [M-Br]+.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-ethyl butanoate-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 6 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was then filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to obtain an orange-red solid product with a yield of 40%. Into 4.0 mmol of the obtained reaction product were added 4.2 mmol of 1-(2-hydroxyethyl)-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:14 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-6 compound in a yield of 43%. MS (EI) C27H29N2O3S m/z: 461.2 [M-Br]+.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-(2-phenoxyethyl)-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 5 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was then filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to obtain an orange-red solid product in a yield of 47%. Into 4.0 mmol of the obtained reaction product were added 4.2 mmol of 1-benzyl-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate dark purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:10 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-7 compound in a yield of 46%. MS (EI) C34H29BrN2OS m/z:513.2[M-Br]+.
In a mixed solution of 40 mL of methanol and 20 mL of ethanol, 10 mmol of 1-(2-phenoxyethyl)-2-methylbenzothiazolium bromide and 30 mmol of N,N′-diphenylformamidine were heated while stirring in a 65° C. oil bath for 5 hours. After the reaction was completed, the solvents were distilled off under reduced pressure. Then an amount of ethyl ether was added and stirred to precipitate orange solid powder which was then filtered and dried. The crude product was recrystallized in ethyl acetate-hexane to obtain an orange-red solid product with a yield of 47%. Into 4.0 mmol of the obtained reaction product were added 4.5 mmol of 1-(4-methoxyphenylethyl)-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 90° C. oil bath for 1.5 hours. The reaction was cooled down to room temperature and then poured into ethyl ether to precipitate purple-red solids which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:7 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-8 compound in a yield of 51%. MS (EI) C35H31BrN2O2S m/z: 543.2 [M-Br]+.
In 20 ml of solvents (acetic acid: acetic anhydride=1:1), 8 mmol of 1-(2-phenoxyethyl)-2-methylbenzothiazolium bromide and 10 mmol of malonaldehyde diphenylimine hydrochloride were heated to 120° C. for 1 hour. Then the reaction mixture was cooled and ethyl ether was added to precipitate solids. The solids were filtered and washed with 30 mL of ethyl acetate three times to remove the excess unreacted condensing agent. Then the solids were dried to give brown-yellow powder with a crude yield of 68%. Into 4.0 mmol of the obtained reaction product were added 6 mmol of 1-(2-hydroxyethyl)-4-methylquinolinium salt and 10 ml of pyridine, and the mixture was heated while stirring in a 110° C. oil bath for 1 hour. The reaction was cooled and then poured into ethyl ether to precipitate small dark purple particles which were then filtered and dried. The dye was separated through a silica column using dichloromethane:methanol=100:15 as the eluent. The blue fractions were collected and dried in a vacuum drying oven at 45° C. for 24 hours to obtain the exemplary Dye-9 compound in a yield of 43%. MS (EI) C31H29BrN2O2S: m/z: 493.2 [M-Br]+.
An amount of Dye-1 was accurately weighed and sufficiently dissolved in 2.5 mL methanol/ethylene glycol (50:50 vol/vol) to prepare a dye solution at a concentration of 5 mM. This solution was filtered before use. Separate amounts of salmon sperm DNA were weighed and dissolved in PBS to obtain PBS buffers containing 3 mg/mL, 1 mg/mL, 0.3 mg/mL, 0.1 mg/mL of DNA. 2-μL aliquots of the prepared 5 mM dye solution were accurately measured and respectively combined in 1 mL PBS with 1 μL of the PBS buffers containing different concentrations of DNA. After reacting for a period of time, the complexes were detected for their emission spectra at the selected excitation wavelength of 633 nm. The detection temperature was at room temperature. The instrument used was fluorescence spectrophotometer Model FL-4500. The results were as shown in
An amount of Dye-1 was accurately weighed and sufficiently dissolved in 2.5 mL methanol/ethylene glycol (50:50 vol/vol) to prepare a dye solution at a concentration of 5 mM. This solution was filtered before use. Separate amounts of soft-shelled turtle (Trionyx sinensis) liver RNA were weighed and dissolved in PBS to obtain PBS buffers containing 30 μg/mL, 10 μg/mL, 3 μg/mL, 1 μg/mL of RNA. 2-μL aliquots of the prepared 5 mM dye solution were accurately measured and respectively combined in 1 mL PBS with 1 μL of the PBS buffers containing different concentrations of RNA. After reacting for a period of time, the complexes were detected for their emission spectra at the selected excitation wavelength of 633 nm. The detection temperature was at room temperature. The instrument used was fluorescence spectrophotometer Model FL-4500. The results were as shown in
The detection procedures followed were those described in Example 10 and Example 11. The fluorescence spectra for the complexes of Dye-2 with different concentrations of DNA or RNA are shown in
The detection procedures followed were those described in Example 10 and Example 11. The comparisons of fluorescence for Dye-3 before and after it bound with DNA or with RNA in PBS are shown in
Table 1 compares the ratios of increase in fluorescence for Dye-1, Dye-2 and Dye-3 after vs before they bound with salmon sperm DNA in PBS.
Table 2 compares the ratios of increase in fluorescence for Dye-1, Dye-2 and Dye-3 after vs before they bound with soft-shelled turtle (Trionyx sinensis) liver RNA in PBS.
To illustrate how the compounds of the present disclosure improve the properties of fluorescent dyes, the known compound Dye-0 having the following structure is selected as the reference (Journal of the American Chemical Society (1945) 67, 18889-93):
The detection procedure followed was that described in Example 10. The fluorescence spectra for Dye-1, Dye-2 and Dye-0 after they bound in identical concentrations with soft-shelled turtle (Trionyx sinensis) liver RNA are shown in
Separate solutions of Dye-1, Dye-2, Dye-3 and Dye-0 in ethanol were prepared in concentrations that resulted in a maximum absorbance <0.1 on a UV-Vis spectrophotometer and were detected for their fluorescence intensities at selected excitation wavelengths. Each of the dyes were detected in triplicate at room temperature. Fluorescence quantum yields were calculated and averaged. With Rhodamine B as the standard (φF=0.97, ethanol), the fluorescence quantum yield for the known compound M in the ethanol solution was calculated to be φF=1.099×10−2; for Dye-1, φF=1.590×10−2; for Dye-2, φF=1.248×10−2; and for Dye-3, φF=1.181×10−2. The instrument used was UV-Vis spectrophotometer Model Lambda 35, and fluorescence spectrophotometer Model FL-4500.
Data showed that the compounds of the present disclosure exhibited a higher fluorescence quantum yield than the known compound.
Although the present disclosure has been illustrated by way of the above embodiments and particular examples thereof, it will be appreciated by those skilled in the art that various changes, alterations and modifications may be made to the present disclosure without departing from the spirit and scope of the present invention as claimed.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2008 1 0002503 | Jan 2008 | CN | national |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3883247 | Adams | May 1975 | A |
| 3883274 | Vuaille | May 1975 | A |
| 4122348 | Bruck | Oct 1978 | A |
| 4146604 | Kleinerman | Mar 1979 | A |
| 4286963 | Ledis et al. | Sep 1981 | A |
| 4325706 | Gershman et al. | Apr 1982 | A |
| 4332785 | Allen et al. | Jun 1982 | A |
| 4336029 | Natale | Jun 1982 | A |
| 4386146 | Kishino et al. | May 1983 | A |
| 4414325 | Masuda et al. | Nov 1983 | A |
| 4447547 | Allen et al. | May 1984 | A |
| 4485175 | Ledis et al. | Nov 1984 | A |
| 4528274 | Carter et al. | Jul 1985 | A |
| 4529705 | Larsen | Jul 1985 | A |
| 4544546 | Wang et al. | Oct 1985 | A |
| 4571388 | O'Connell et al. | Feb 1986 | A |
| 4596035 | Gershman et al. | Jun 1986 | A |
| 4617275 | Matsuda et al. | Oct 1986 | A |
| 4637986 | Brown et al. | Jan 1987 | A |
| 4707451 | Sage et al. | Nov 1987 | A |
| 4745071 | Lapicola et al. | May 1988 | A |
| 4751179 | Ledis et al. | Jun 1988 | A |
| 4822745 | Burns et al. | Apr 1989 | A |
| 4882284 | Kirchanski et al. | Nov 1989 | A |
| 4883867 | Lee et al. | Nov 1989 | A |
| 4933293 | Kuroda et al. | Jun 1990 | A |
| 4957870 | Lee et al. | Sep 1990 | A |
| 4971917 | Kuroda | Nov 1990 | A |
| 4978624 | Cremins et al. | Dec 1990 | A |
| 4981803 | Kuroda | Jan 1991 | A |
| 4985174 | Kuroda et al. | Jan 1991 | A |
| 5039613 | Matsuda et al. | Aug 1991 | A |
| 5075556 | Fan et al. | Dec 1991 | A |
| 5116539 | Hamaguchi et al. | May 1992 | A |
| 5155044 | Ledis et al. | Oct 1992 | A |
| 5175109 | Sakata et al. | Dec 1992 | A |
| 5179026 | Matsuda et al. | Jan 1993 | A |
| 5180677 | Di Ianni et al. | Jan 1993 | A |
| 5188935 | Leif et al. | Feb 1993 | A |
| 5227304 | Wong | Jul 1993 | A |
| 5232857 | Lefevre et al. | Aug 1993 | A |
| 5242832 | Sakata | Sep 1993 | A |
| 5250437 | Toda et al. | Oct 1993 | A |
| 5264369 | Sakata et al. | Nov 1993 | A |
| 5284771 | Fan et al. | Feb 1994 | A |
| 5316725 | Carver et al. | May 1994 | A |
| 5316951 | Carver et al. | May 1994 | A |
| 5321130 | Yue et al. | Jun 1994 | A |
| 5350695 | Colella et al. | Sep 1994 | A |
| 5360739 | Fan et al. | Nov 1994 | A |
| 5389549 | Hamaguchi et al. | Feb 1995 | A |
| 5411891 | Fan et al. | May 1995 | A |
| 5413938 | Tsujino et al. | May 1995 | A |
| 5438003 | Colella et al. | Aug 1995 | A |
| 5486477 | Carver et al. | Jan 1996 | A |
| 5492833 | Rodriguez et al. | Feb 1996 | A |
| 5496734 | Sakata et al. | Mar 1996 | A |
| 5510267 | Marshall | Apr 1996 | A |
| 5516695 | Kim et al. | May 1996 | A |
| 5518928 | Cremins et al. | May 1996 | A |
| 5538893 | Sakata et al. | Jul 1996 | A |
| 5559037 | Kim et al. | Sep 1996 | A |
| 5563070 | Yamamoto et al. | Oct 1996 | A |
| 5616501 | Rodriguez et al. | Apr 1997 | A |
| 5618733 | Sakata et al. | Apr 1997 | A |
| 5633167 | Fan et al. | May 1997 | A |
| 5639630 | Malin et al. | Jun 1997 | A |
| 5639666 | Shenkin et al. | Jun 1997 | A |
| 5656449 | Yue | Aug 1997 | A |
| 5677183 | Takarada et al. | Oct 1997 | A |
| 5686308 | Li et al. | Nov 1997 | A |
| 5691204 | Kim et al. | Nov 1997 | A |
| 5731206 | Ledis et al. | Mar 1998 | A |
| 5733784 | Studholme et al. | Mar 1998 | A |
| 5747343 | Tsuchiya et al. | May 1998 | A |
| 5763280 | Li et al. | Jun 1998 | A |
| 5773299 | Kim et al. | Jun 1998 | A |
| 5786224 | Li et al. | Jul 1998 | A |
| 5817518 | Li et al. | Oct 1998 | A |
| 5821127 | Akai et al. | Oct 1998 | A |
| 5821128 | Provost | Oct 1998 | A |
| 5840515 | Provost | Nov 1998 | A |
| 5843608 | Li et al. | Dec 1998 | A |
| 5858667 | Dertinger et al. | Jan 1999 | A |
| 5874311 | Li et al. | Feb 1999 | A |
| 5879900 | Kim et al. | Mar 1999 | A |
| 5882934 | Li et al. | Mar 1999 | A |
| 5891731 | Akai et al. | Apr 1999 | A |
| 5928949 | Sakata et al. | Jul 1999 | A |
| 5958776 | Sakata et al. | Sep 1999 | A |
| 5968832 | Uchihashi et al. | Oct 1999 | A |
| 5994089 | Siiman et al. | Nov 1999 | A |
| 5994138 | Veriac | Nov 1999 | A |
| 6004816 | Mizukami et al. | Dec 1999 | A |
| 6060322 | Horton et al. | May 2000 | A |
| 6100038 | Dertinger et al. | Aug 2000 | A |
| 6114130 | Veriac et al. | Sep 2000 | A |
| 6114173 | Zelmanovic et al. | Sep 2000 | A |
| 6197593 | Deka et al. | Mar 2001 | B1 |
| 6245499 | Suzuki et al. | Jun 2001 | B1 |
| 6271035 | Deka et al. | Aug 2001 | B1 |
| 6287791 | Terstappen et al. | Sep 2001 | B1 |
| 6350613 | Wardlaw et al. | Feb 2002 | B1 |
| 6368864 | Deka et al. | Apr 2002 | B1 |
| 6495692 | Wang et al. | Dec 2002 | B1 |
| 6524858 | Zelmanovic et al. | Feb 2003 | B1 |
| 6551831 | Gupta et al. | Apr 2003 | B2 |
| RE38131 | Uchihashi et al. | Jun 2003 | E |
| 6630990 | van't Dever et al. | Oct 2003 | B2 |
| 6632676 | Crews et al. | Oct 2003 | B1 |
| 6664110 | Tsuji et al. | Dec 2003 | B1 |
| 6794152 | Ryan et al. | Sep 2004 | B2 |
| 6869798 | Crews et al. | Mar 2005 | B2 |
| 6900023 | Houwen et al. | May 2005 | B1 |
| 6955872 | Maples et al. | Oct 2005 | B2 |
| 6977156 | Ryan et al. | Dec 2005 | B2 |
| 7083982 | Wang et al. | Aug 2006 | B2 |
| 7235404 | Lang et al. | Jun 2007 | B2 |
| 7247484 | Wu et al. | Jul 2007 | B2 |
| 7300797 | van Agthoven et al. | Nov 2007 | B2 |
| 7405082 | Mizukami et al. | Jul 2008 | B2 |
| 7449337 | Deka et al. | Nov 2008 | B2 |
| 7465584 | Matsumoto et al. | Dec 2008 | B2 |
| 20020182623 | Lefevre et al. | Dec 2002 | A1 |
| 20030145394 | Wang et al. | Aug 2003 | A1 |
| 20040241769 | Crews et al. | Dec 2004 | A1 |
| 20050202400 | Tsuji et al. | Sep 2005 | A1 |
| 20050272026 | Oguni | Dec 2005 | A1 |
| 20060177347 | Larsen et al. | Aug 2006 | A1 |
| 20070111276 | Lefevre et al. | May 2007 | A1 |
| 20070178597 | Tsuji et al. | Aug 2007 | A1 |
| 20080026475 | van Agthoven et al. | Jan 2008 | A1 |
| 20080131898 | Tsuji et al. | Jun 2008 | A1 |
| 20080176274 | Tsuji et al. | Jul 2008 | A1 |
| 20090023129 | Xu et al. | Jan 2009 | A1 |
| 20090176270 | Shao | Jul 2009 | A1 |
| 20100151509 | Ting et al. | Jun 2010 | A1 |
| 20100178654 | Kataoka et al. | Jul 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 1101980 | Apr 1995 | CN |
| 1101982 | Apr 1995 | CN |
| 1183559 | Jun 1998 | CN |
| 1202621 | Dec 1998 | CN |
| 1149397 | May 2004 | CN |
| 0548983 | Jun 1993 | EP |
| 0794435 | Sep 1997 | EP |
| WO03104771 | Dec 2003 | WO |
| WO9717471 | May 2004 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20090176270 A1 | Jul 2009 | US |
